The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Abstract
Incretin-based therapies, including the use of incretin mimetics of glucagon-like peptide-1 receptor (GLP-1R) agonists and incretin enhancers of dipeptidyl-peptidase 4 (DPP-4) inhibitors, are widely used by clinicians for glucose lowering in patients with type 2 diabetes mellitus. These agents have benefits of a lower risk of hypoglycemia, being neutral for body weight for DPP-4 inhibitors and having a potential for weight reduction with GLP-1R agonists. They may also have a neutral or beneficial cardiovascular effect. Despite these benefits, an increased risk of cancer (especially pancreatic cancer and thyroid cancer) associated with incretin-based therapies has been reported. In this article, we reviewed related literature of experimental animal and observational human studies, clinical trials, and meta-analyses published until December 15, 2014. Current studies suggested a probable role of GLP-1R activation on the development of pancreatic cancer and thyroid cancer in rodents, but such an effect in humans is not remarkable due to the lower or lack of expression of GLP-1R on human pancreatic ductal cells and thyroid tissues. Findings in human studies are controversial and inconclusive. In the analyses of the US Food and Drug Administration adverse events reporting system, a significantly higher risk of pancreatic cancer was observed for GLP-1R agonists and DPP-4 inhibitors, but a significantly higher risk of thyroid cancer was only observed for GLP-1R agonists. Such a highe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There has been considerable interest in a potential association between the use of GLP-1–receptor agonists and pancreatitis and pancreatic cancer, although there is no consistent preclinical, pharmacovigilance, or epidemiologic evidence to date.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [25]
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Cancer cells are highly dependent on hyperglycemia for survival (Warburg effect) [182].”
BackgroundGlobal estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Therapeutic approaches for enhancing incretin action include the use of the injection form of degradation-resistant GLP-1 receptor (GLP-1R) agonists (incretin mimetics) and the oral form of DPP-4 inhibitors (incretin enhancers) [65, 66].”
BackgroundSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 5×
“In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 trial (SAVOR–TIMI53) [117], 16,492 patients with type 2 diabetes mellitus were enrolled (saxagliptin group 8280, placebo 8212).”
BackgroundMethodResultInfluentialAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 7×
“It is worthy to note that there were no cases of pancreatic cancer reported in this trial [118].”
BackgroundMethodResultInfluentialCurrent Thyroid Cancer Trends in the United States
Davies, L., & Welch, H. G. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1 · Cited by 1,615 · cited 1×
“Since PTC is more common and has greater epidemiologic significance than C-cell neoplasm [163, 164], the impact of longterm GLP-1R stimulation on thyroid neoplasm needs continuous monitoring, especially for PTC [75].”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 7×
“Traditional Risk Factors for Cancer Information of important confounders of pancreatic cancer such as obesity, smoking, alcohol consumption, and chronic pancreatitis is lacking in the FDA adverse events reporting system that showed an increased risk of pancreatic cancer associated with incretin-based therapies [46, 74…”
BackgroundMethodResultInfluentialPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 9×
“Although a study conducted in ob/ob mice suggested that exendin-4 treatment might reverse hepatic steatosis [148], a recent study did not support the existence of GLP-1R in liver cells of primates including monkeys and humans [59].”
BackgroundMethodResultInfluentialEnewold, L., Zhu, K., Ron, E., Marrogi, A. J., Stojadinovic, A., Peoples, G. E., & Devesa, S. S. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0960 · Cited by 809 · cited 1×
“Since PTC is more common and has greater epidemiologic significance than C-cell neoplasm [163, 164], the impact of longterm GLP-1R stimulation on thyroid neoplasm needs continuous monitoring, especially for PTC [75].”
Background
Research works printed but not linked: 9
- International Diabetes Federation Diabetes Atlas, 6th ed.
- Lin HW, 2014, Int J Endocrinol, 2014, 719578
- 10.1210/endo.141.12.7806 · doi:10.1210/endo.141.12.7806 · Paper page
- Faillie JL, 2014, Acta Diabetol, 51, 491
- 10.2967/jnumed.106.038679 · DOI · Paper page
- Huang CJ, 2014, J Chin Med Assoc
- Navas-Carrillo D, 2014, Biochim Biophys Acta, 1846, 468
- Nagy R, 2014, Horm Cancer
- Kwon MJ, 2014, Pancreas
Cited by
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L., Booth, G., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 246
“GLP-1 receptor agonists have been shown to promote the development of pancreatic and medullary thyroid cancer in rodents, but an increased risk has not been seen in humans (138).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1611289 · Cited by 195
Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment
Suh, S., & Kim, K.-W. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0177 · Cited by 185
Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
Tseng, C. (2016) · Aging · doi:10.18632/aging.101019 · Cited by 86
“In contrast to other antidiabetic drugs (including sulfonylurea, insulin, thiazolidinediones and incretinbased therapies) that may show an increased risk of cancer [10-16], metformin was first noted to be associated with a reduced risk of cancer in an observational study in 2005 [17].”
ResultSelf-citation
Metadata
- Authors
- Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H.
- Affiliations
- National Taiwan University Hospital (TW)
- China Medical University Hospital (TW)
- University of Southern California (US)
- Corresponding author
- Tseng, Chin-Hsiao
- Venue
- Journal of Environmental Science and Health, Part C
- Publisher
- Informa UK Limited
- Published
- 2015-01-02
- Volume
- 33
- Issue
- 1
- Pages
- 67-124
- ISSN
- 1059-0501 (ISSN-L)
- 1532-4095
- OpenAlex
- W2140307375
- Cited by
- 49
- References
- 195
- Citations by year
- 2025: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 13 · 2015: 3
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Environmental Science and Health Part C (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, cancer risk, pancreatic cancer, thyroid cancer, type 2 diabetes, adverse drug reactions
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Pancreatic Neoplasms, Risk Factors, Thyroid Neoplasms, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. https://app.cochat.ai/papers/10.1080/10590501.2015.1003496
- The paper
- Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015). An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C. https://doi.org/10.1080/10590501.2015.1003496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.